CD8 ؉ T-cells secrete soluble factor(s) capable of inhibiting both R5-and X4-tropic strains of human immunodeficiency virus type 1 (HIV-1). CCR5 chemokine ligands, released from activated CD8 ؉ T-cells, contribute to the antiviral activity of these cells. These CC-chemokines, however, do not account for all CD8 ؉ T-cell antiviral factor(s) (CAF) released from these cells, particularly because the elusive CAF can inhibit the replication of X4 HIV-1 strains that use CXCR4 and not CCR5 as a coreceptor. Here we demonstrate that activated CD8 ؉ T-cells of HIV-1-seropositive individuals modify serum bovine antithrombin III into an HIV-1 inhibitory factor capable of suppressing the replication of X4 HIV-1. These data indicate that antithrombin III may play a role in the progression of HIV-1 disease.Soluble inhibitory factors produced by CD8 ϩ T-cells have been shown to inhibit HIV-1 1 replication and may play a critical role in vivo in antiviral host defense (1). These inhibitory factors include CC-chemokines (2-4), which bind to the CCR5 coreceptor and inhibit R5 viral entry into cells (1) (5-7), as well as less well characterized soluble factor(s) produced by CD8 ϩ T-cells and termed CD8 ϩ T-cell antiviral factor(s) (CAF), which are capable of inhibiting both R5 and X4 .Recently, we demonstrated that there are two factors produced by activated CD8 ϩ T-cells capable of inhibiting the X4 strain HIV-1 IIIB (16). These factors are distinctive in size and the ability to bind heparin. One of these factors bound heparin at physiological salt concentration, eluted at 350 mM NaCl, and was retained by a 50-kDa cut-off Centricon filter. The other factor did not bind heparin at physiological salt concentration and was filtered through a 50-kDa cut-off Centricon filter. The HIV-1 inhibitory activity of these factors was higher with bulk CD8 ϩ T-cells of seropositive individuals and HIV-1-specific cytotoxic T-lymphocytes (CTL) compared with bulk CD8 ϩ Tcells of HIV-1-seronegative individuals (16). In the present study we identified the heparin binding inhibitory activity as a CD8 ϩ T-cell modified form of antithrombin, which is produced in higher amounts by HIV-1-specific CTL and bulk CD8 ϩ Tcells of seropositive individuals than by bulk CD8 ϩ T-cells of seronegative individuals. In this study for the first time we demonstrate that CD8 ϩ T-cells can activate a serum protein to become inhibitory for HIV, a possibility that has not been addressed previously.
EXPERIMENTAL PROCEDURESHIV-specific CTL Clones and Bulk CD8 ϩ T-Cells-Polyclonal CD8 ϩ cells that were 90 -99% CD3 ϩ -and CD8 ϩ -positive were generated by fluorescence-activated cell sorting from the six seronegative and six HIV-1-seropositive long-term nonprogressors by positive selection with anti-CD8 antibody-coated immunomagnetic beads (PerSeptive Biosystems, Framingham, MA) as described (16). HIV-1-specific CTL clones were used as described (16). Bulk CD8 ϩ cell lines from seropositive and seronegative persons were established by incubating purified CD8 ϩ cells (2 ϫ 10 6 )...